Will Kinase Inhibitors Make it as Glioblastoma Drugs?
- Ingo K. MellinghoffAffiliated withHuman Oncology and Pathogenesis Program, Department and Neurology, Memorial Sloan-Kettering Cancer Center Email author
- , Nikolaus SchultzAffiliated withComputational Biology Program, Memorial Sloan-Kettering Cancer Center
- , Paul S. MischelAffiliated withDepartment of Pathology, University of California Los Angeles
- , Timothy F. CloughesyAffiliated withDepartment of Neurology, University of California Los Angeles
Kinase inhibitors have emerged as effective cancer therapeutics in a variety of human cancers. Glioblastoma (GBM), the most common malignant brain tumor in adults, represents a compelling disease for kinase inhibitor therapy because the majority of these tumors harbor genetic alterations that result in aberrant activation of growth factor signaling pathways. Attempts to target the Ras—Phosphatidylinositol 3-kinase (PI3K)—mammalian Target of Rapamycin (mTOR) axis in GBM with first generation receptor tyrosine kinase (RTK) inhibitors and rapalogs have been disappointing. However, there is reason for renewed optimism given the now very detailed knowledge of the cancer genome in GBM and a wealth of novel compounds entering the clinic, including next generation RTK inhibitors, class I PI3K inhibitors, mTOR kinase inhibitors (TORKinibs), and dual PI3(K)/mTOR inhibitors. This chapter reviews common genetic alterations in growth factor signaling pathways in GBM, their validation as therapeutic targets in this disease, and strategies for future clinical development of kinase inhibitors for high grade glioma.
- Will Kinase Inhibitors Make it as Glioblastoma Drugs?
- Book Title
- Therapeutic Kinase Inhibitors
- pp 135-169
- Print ISBN
- Online ISBN
- Series Title
- Current Topics in Microbiology and Immunology
- Series Volume
- Series ISSN
- Springer Berlin Heidelberg
- Copyright Holder
- Springer-Verlag Berlin Heidelberg
- Additional Links
- Industry Sectors
- eBook Packages
- Editor Affiliations
- ID1. , Human Oncology & Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
- ID2. , Human Oncology & Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
- Author Affiliations
- 1. Human Oncology and Pathogenesis Program, Department and Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- 2. Computational Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- 3. Department of Pathology, University of California Los Angeles, Los Angeles, CA, USA
- 4. Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA
To view the rest of this content please follow the download PDF link above.